Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Jorge E. Cortes, MD, on Standard vs Alternate Dosing of Ponatinib in Chronic Phase CML

Posted: Monday, July 13, 2020

Jorge E. Cortes, MD, of Georgia Cancer Center, talks about how the OPTIC trial results on different doses of ponatinib might lead to an alternate dosing regimen for patients with chronic phase chronic myeloid leukemia and the challenges associated with standard dosing.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.